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Abstract
Background: High mobility group box-1 (HMGB1) is a newly recognized factor regulating cancer
cell tumorigenesis, expansion and invasion. We investigated the correlation between the serum
HMGB1 levels and the clinical and pathologic features of gastric cancer and evaluated the validity
of HMGB1 as a potential biomarker for the early diagnosis of gastric cancer.
Methods: A total of 227 subjects were classified into 5 disease groups according to the 'gastritis-
dysplasia-carcinoma' sequence of gastric carcinogenesis and their serum levels of HMGB1 were
analyzed by an enzyme-linked immunosorbent assay (ELISA) method. Clinical parameters,
International Union Against Cancer (UICC) TNM stage, cancer size, differentiation or lymphatic
invasion, vascular or perineural invasion and prognosis were used as analysis variables.
Results: The serum HMGB1 levels were significantly different among disease groups (ANOVA, p
< 0.05) and HMGB1 levels tended to increase according to the progression of gastric
carcinogenesis. Serum HMGB1 levels were significantly associated with depth of invasion, lymph
node metastasis, tumor size, and poor prognosis (p < 0.05). However, HMGB1 levels were not
associated with patient gender or age, differentiation of tumor cells, or lymphatic, vascular and
perineural invasion, or the existence of distant metastasis in advanced cancer (p > 0.05). The
sensitivity and specificity of serum HMGB1 was 71% and 67% (cut-off value of 5 ng/ml) for the
diagnosis of early gastric cancer, and 70% and 64% (cut-off value of 4 ng/ml) for the diagnosis of
high-risk lesions, respectively. These values were greater than those for carcinoembryonic antigen
(CEA) (30–40% of sensitivity).
Conclusion: HMGB1 appears to be a useful serological biomarker for early diagnosis as well as
evaluating the tumorigenesis, stage, and prognosis of gastric cancer.
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Background
A group of molecules that may act as mediators of angio-
genesis are the so-called high-mobility group proteins. An
important member of this superfamily is high mobility
group box-1 (HMGB1) which was originally characterized
as a non-histone, nuclear DNA-binding protein [1,2].
HMGB1 has been recently demonstrated to serve as a
cytokine that mediates late lethal systemic inflammation
via its extracellular release from activated macrophages/
monocytes and cells undergoing necrosis [3-5]. The con-
stant release of HMGB1, which functions as a proinflam-
matory cytokine, from necrotic tumor cells creates a
microenvironment similar to chronic inflammation; a
condition known to contribute to the development of epi-
thelial malignancies, particularly inflammation-associ-
ated cancer [6]. In fact, many previous studies have
demonstrated the over-expression of HMGB1 with its
receptor, receptor for advanced glycation end products
(RAGE), in different tumor types, including breast carci-
noma [7], colorectal cancer [8], prostate cancer [9], pan-
creatic cancer [10], and hepatocellular carcinoma [11].
Moreover, these studies showed that the over-expression
of HMGB1 is strongly correlated with tumor invasiveness
[7-13].
Multiple steps and multiple factors are involved in the
development of gastric cancer (GC). Among these factors,
chronic inflammation is important particularly in the
intestinal type of GC. The Correa hypothesis postulates
that a progression from chronic gastritis to gastric atrophy,
intestinal metaplasia (IM), dysplasia, and finally to cancer
('gastritis-dysplasia-carcinoma' sequence) [14]. In each
step of GC progression many cytokines and intracellular
signaling are involved [14].
Several studies have demonstrated that HMGB1 is over-
expressed in approximately 85% of GC [15]. In addition,
the over-expression of HMGB1 in GC is reported to be
associated with tumor invasiveness and metastasis [15-
17]. In almost all of these studies, the over-expression of
HMGB1 has been documented in tissues by measuring
mRNA levels via in situ hybridization or immunohisto-
chemical analysis [7-10,15-17], but there is little informa-
tion about the corresponding serological activity of
HMGB1 and the progression of GC. Although the meas-
urement of HMGB1 activity in tissues is clinically impor-
tant, this method of biomarker analysis is somewhat
limited because the measurement of biomarker activity in
tissue requires invasive techniques such as endoscopy and
biopsy, that are associated with patient discomfort and
risk. HMGB1 could be measured in serum and used as a
serologic tumor biomarker because it can be released into
extracellular environment like other cytokines [6,11].
Although the overall incidence of GC has decreased in
most countries over the past few decades, it is still a seri-
ous health problem [18]. The prognosis of advanced gas-
t r i c  c a n c e r  ( A G C )  w i t h  e x t e n s i v e  n o d e  i n v a s i o n  a n d
metastasis remains poor while early gastric cancer (EGC)
is associated with excellent long-term survival [19]. There-
fore, efforts to identify a serum biomarker that could be
used to detect early stage GC or premalignant lesions as
well as to estimate tumor invasion and predict prognosis
are of great clinical importance. Although carcinoembry-
onic antigen (CEA) is a well-known tumor marker of GC,
it is considered to be neither sensitive nor specific for GC
screening [20,21].
In this study we measured serum HMGB1 and CEA levels
and evaluated the correlation of these values with the pro-
gression of gastric carcinogenesis. We then estimated the
validity of HMGB1 as a potential biomarker for the
screening, diagnosis, and surveillance of GC. We also ana-
lyzed the relationship between serum HMGB1 levels and
the clinical and pathological parameters of GC.
Methods
Subjects
Between March 2007 and July 2008 a total of 227 subjects
were enrolled in this study at Severance Hospital, Gastro-
enterology Department Clinics, Yonsei University Health
System. All subjects underwent upper gastrointestinal
endoscopy (Types XQ-260, Olympus, Tokyo, Japan) with
a biopsy. The final diagnosis was made by histopatholog-
ical studies; via biopsy specimens in the non-cancer
groups and via biopsy and surgical specimens in the can-
cer groups. All cancer patients were diagnosed for the first
time during the enrollment period and their blood sam-
ples were collected before they received any treatment
such as surgery, chemotherapy or radiotherapy. This
research was approved by the Institutional Review Board
of Yonsei University Health System and all participants
gave written informed consent.
Subjects were classified into 5 groups based on endo-
scopic biopsy findings according to the 'gastritis-dyspla-
sia-carcinoma' sequence in gastric carcinogenesis [14];
normal group (including acute and chronic gastritis
(CSG), erosion, and gastric ulcer), high-risk group
(including IM and adenoma), EGC group, AGC group
without distant metastasis, and metastatic GC group
including carcinomatosis (M group). All subjects were
both age- and sex-matched among disease groups.
Subjects were excluded if they suffered from acute infec-
tion or inflammatory disease. They were also excluded if
they had a history of chronic illness such as: autoimmune
disease, rheumatic disease, chronic infection or inflam-
matory disease, or other cancers. Subjects with a history ofJournal of Translational Medicine 2009, 7:38 http://www.translational-medicine.com/content/7/1/38
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previous gastric surgery or any other treatment for GC
such as chemotherapy or radiotherapy were also excluded.
In the cancer groups all patients were evaluated by imag-
ining procedures such as chest X-ray, helical computed
tomography (CT), and whole body Positron Emission
Tomography (PET) scan. This was followed by gastrec-
tomy with lymph node dissection.
Measurement of serum CEA and HMGB1 levels
Approximately 10 ml of whole blood was collected in
non-heparinized tubes from each fasting subject and
allowed to clot at room temperature for half an hour. The
blood was centrifuged at 3,000 rpm for 15 minutes and
the serum fraction was aliquoted and stored at -70°C in
microfuge tubes until assayed. CEA was measured with a
Roche E170 (Roche Diagnostics GmbH, Mannheim, Ger-
many), a modular immunoassay analyzer. HMGB1 was
measured by the commercially available HMGB1 ELISA
Kit II (SHINO-TEST Corporations, Kanagawa, Japan).
Briefly, 100 μl of sample diluent was added to each well
and then 10 μl of standard, and sample or control was
added to the well. The microtiter plates were incubated for
20–24 h at 37°C. After washing, 100 μl/well of anti-
human HMGB1 peroxidase-conjugated monoclonal anti-
body was added and the plates were incubated at room
temperature for 2 h. After washing, the chromogen
3,3',5,5'-tetra-methylbenzidine was added to each well.
The enzyme reaction was allowed to proceed for 30 min
at room temperature. The chromogenic substrate reaction
was stopped by the addition of stop solution (0.35 mol/l
Na2SO4) and the absorbance was read at 450 nm. The
results were calculated using a calibration curve prepared
from standards.
Histopathological analysis
In non-cancer groups two specimens were obtained from
the greater curvature of the antrum and the midpoint of
the greater curvature of the gastric body via endoscopic
biopsy. In the patients with cancer two specimens were
obtained from the cancerous portion of the surgical spec-
imen and adjacent normal mucosa. All formalin-fixed and
paraffin-embedded specimens were stained with 0.7%
Harris hematoxylin solution (w/v) (Sigma, Missouri,
USA) to confirm the pathology and stained with Giemsa
solution (Sigma, Missouri, USA) to detect H. pylori infec-
tion. Glandular atrophy and IM were diagnosed according
to the updated Sydney classification [22]. With surgical
specimens of GC, conventional pathological parameters
of GC (tumor size, tumor location, metastatic distant
organ, depth of invasion, lymph node metastasis, and
lymphovascular and perineural invasion) were analyzed.
Pathological differentiations were classified using Lauren
classification. Stages were analyzed according to the Inter-
national Union Against Cancer (UICC)-TNM stage [23].
Two pathologists who were blind to previous histological
scores and other experimental results determined the his-
topathological results.
Statistical analysis
Values (CEA, HMGB1) in each group were expressed as a
mean with the 25–75% standard deviation range. One-
way analysis of variance (ANOVA) with the multiple com-
parisons by Post HOC Scheffe method was used to com-
pare the mean of each value (CEA, HMGB1) among
groups. Pearson correlation analysis was performed to
assess the correlations between HMGB1 and the continu-
ous variables, and Spearman correlation was performed to
assess the correlations between HMGB1 and the non-con-
tinuous variables. Receiver operating characteristic curves
(ROC) were plotted to determine the best cut-off ranges
for GC screening for each value, and the relevant sensitiv-
ities and specificities were calculated. Survival time was
measured in days from the day of first diagnosis to death
or last review in M group. Overall survival times were ana-
lyzed by the Kaplan-Meier method. Statistical Package for
Social Sciences software (SPSS, Chicago, Illinois, USA ver-
sion 13.0) was used for data support and analysis and p-
values < 0.05 were considered as statistically significant
differences.
Results
Characteristics of the subjects
The 227 subjects studied included 50 patients with nor-
mal gastric mucosa including chronic gastritis and ulcer
(normal group), 50 with IM including adenoma (high
risk group), 40 with EGC (EGC group), 45 with AGC with-
out distant metastasis (AGC group), and 42 with meta-
static GC (M group). The clinical and pathological
characteristics in each subject and their tumor are
described in Table 1. There were no significant differences
among 5 disease groups in demographics such as age, gen-
der, and the status of H. pylori infection (ANOVA, p >
0.05).
Serum levels of CEA and HMGB1 among disease groups
The mean serum CEA and HMGB1 levels were compared
among disease groups (Table 1 and Figure 1). The serum
CEA levels were 1.7 ± 0.8 ng/ml in the normal group, 2.6
± 1.8 ng/ml in the high-risk group, 1.6 ± 0.9 ng/ml in the
EGC group, 3.8 ± 8.1 ng/ml in the AGC group, and 46.3 ±
551.5 ng/ml in M group. No significant differences in CEA
levels were found among the normal, high-risk, EGC, and
AGC groups (ANOVA, p > 0.05). Serum CEA levels were
only significantly greater in M group compared with the
other groups (ANOVA, p < 0.05). (Figure 1A).
The mean serum HMGB1 levels were 3.9 ± 3.4 ng/ml in
the normal group, 6.3 ± 6.3 ng/ml in the high-risk group,
9.9 ± 11.5 ng/ml in the EGC group, 16.5 ± 27.4 ng/ml inJournal of Translational Medicine 2009, 7:38 http://www.translational-medicine.com/content/7/1/38
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the AGC group, and 14.1 ± 13.2 ng/ml in M group. The
serum HMGB1 levels were significantly different among
the each group (ANOVA, p < 0.05). The HMGB1 levels
tended to increase according to the progression of gastric
carcinogenesis. Serum HMGB1 levels in subjects with can-
cer were significantly higher than the levels in those with-
out cancer (p < 0.05), and the HMGB1 levels were also
significantly greater in subjects in high-risk group com-
pared to the normal group (p < 0.05). In the normal
group, the HMGB1 levels were slightly higher in ulcer
group than non-ulcer group, but the difference was not
statistically significant (p > 0.05) (Figure 1B).
Relationship between serum CEA or HMGB1 levels and 
clinical andpathological characteristics
When all subjects were included in the analysis, there was
no relationship between the serum CEA level and age
(Pearson correlation coefficients, γp = 0.095, p > 0.05) or
gender (Spearman correlation coefficients, γs = -0.044, p >
0.05) (Table 2). Serum HMGB1 levels were also not
Table 1: Baseline clinico-pathologic characteristics and serum level of CEA or HMGB1 according to disease groups
Groups of diseases (n) Normal (50) High-risk Group (50)* EGC Group (40) AGC Group (45) Metastatic GC group (42)
Clinical factors
Age (mean ± S.D; year) 56.0 ± 13 57.5 ± 12.3 61.5 ± 12.0 59.8 ± 13.7 54.7 ± 11.9
Male/female (n) 32:18 31:19 25:15 28:17 26:16
H. pylori infection (-/+, n) 21:29 30:20 18:22 27:18 20:22
Pathological factors
Size of main tumor (cm) NS NS 4.1 ± 2.7 9.2 ± 5.9 11.8 ± 4.6
Differentiation NS NS
Intestinal type 25 21 14
Diffuse type 15 24 28
Tumor location NS NS
Antrum/Body 31 28 21
Cardia 9 10 12
Diffuse 0 7 7
Depth of invasion NS NS
m, sm 24, 16 2, 0 0, 0
mp, ss 0 9, 13 3, 10
se, a1–3 0 19, 2 1, 0
Lymph-node metastasis NS NS
N0 39 9 1
N1 1 17 2
N2 0 10 3
N3 0 9 8
Lymphovascular invasion (-/+) NS NS 33: 7 10: 35 6: 10
Distant metastatic organ NS NS NS NS
Liver 18
Peritoneum 19
Others† 16
Stage NS NS
I4 0
II 19
III 26
IV 42
Serum CEA (ng/ml)‡ 1.7 ± 0.8 2.6 ± 1.8 1.6 ± 0.9 3.8 ± 8.1 46.3 ± 551.5
Serum HMGB1 (ng/ml)§ 3.9 ± 3.4 6.3 ± 6.3 9.9 ± 11.5 16.5 ± 27.4 14.1 ± 13.2
EGC, early gastric cancer; ACG, advanced gastric cancer; GC, gastric cancer; H. pylori, Helicobacter pylori; mucosa; sm, sub-mucosa; mp, muscularis 
propria; ss, sub-serosa; se, serosa, a1, adventitia; a2, definite invasion into adventitia; a3, invasion into neighboring structures; N0, no lymph node 
metastases; N1, 1 to 6 regional lymph node metastases; n2, 7 to 15; N3, greater than 15; NS, not studied.
*This group includes intestinal metaplasia and adenoma.
† Others include ovary, pancreas, colon, bone, adrenal gland, lung, etc.
‡Serum CEA level was not significantly different among normal, high-risk, EGC, and AGC groups (ANOVA, p > 0.05). It was merely significantly 
higher in metastatic GC group (M group) compared with other groups (p <0.05).
§Serum HMGB1 level was significantly difference among normal, high-risk, EGC, AGC, and M groups (ANOVA, p <0.05). And serum HMGB1 level 
tended to increase according to the progression of the gastric carcinogenesis.
¶Pathological factors such as depth of invasion, node metastasis, frequency of lymphovascular or perineural invasion were not fully investigated in M 
group because most of patients in this stage could not be received an operation.Journal of Translational Medicine 2009, 7:38 http://www.translational-medicine.com/content/7/1/38
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Serum levels of CEA and HMGB1 according to disease group Figure 1
Serum levels of CEA and HMGB1 according to disease group. Figure 1A shows that the serum levels of CEA were not 
significantly different among disease groups except for the metastatic GC group (M group). The serum levels of CEA in M 
group (*) were significantly higher than those of the other groups (Fig 1A, ANOVA with Post HOC Scheffe, p < 0.01). Figure 
1B showed that the serum levels of HMGB1 were significant different among all disease groups and tended to increase accord-
ing to the progression of the gastric carcinogenesis (ANOVA with Post HOC Scheffe, p < 0.05). However, HMGB1 levels were 
not significantly different between the AGC group (*) and M group (†) (ANOVA with Post HOC Scheffe, p > 0.05). GC, gastric 
cancer; EGC, early gastric cancer; AGC, advanced gastric cancer.
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related to age (γp = 0.095, p > 0.05), or gender (γs = -0.106,
p > 0.05) although HMGB1 levels were slightly higher in
males (Table 2). Neither CEA nor HMGB1 levels were
influenced by H. pylori infection in any of the disease
groups (γs = -0.046, p > 0.05 and γs = -0.121, p > 0.05,
respectively) (Table 2). In addition, there was no signifi-
cant correlation between HMGB1 and CEA levels in any of
the disease groups (Pearson correlation = 0.081, p > 0.05)
(Table 2).
Correlation between serum CEA or HMGB1 levels and the 
pathological differentiation of GC
According to the Lauren classification system (intestinal
vs. diffuse type), no significant difference in either CEA or
HMGB1 levels was found among all differentiation
groups; the Spearman correlation coefficients (γs) were -
0.040 (p > 0.05) and -0.009 (p > 0.05), respectively (Table
3).
Tumor location had no effect on HMGB1 (ANOVA, p >
0.05) or CEA levels (ANOVA, p > 0.05) (Table 3), and in
GC patients with metastatic lesions (M group), there was
no difference in serum HMGB1 levels (ANOVA, p > 0.05)
or CEA levels (ANOVA, p > 0.05) (Table 3) according to
distant metastatic organs.
We divided the patients with measurable GC into three
groups by primary tumor size: < 3 cm; 3–5 cm and > 5 cm
in order to analyze the relationship between the serum
HMGB1 levels and GC size (Table 3). There were signifi-
cant differences among the three groups (ANOVA, p <
0.05, Table 1), and a significant positive correlation
between HMGB1 level and tumor size (Spearman correla-
tion coefficients, γs = 0.457, p < 0.05). However, there was
no significant correlation between CEA levels and tumor
size (Spearman correlation coefficients, γs = 0.147, p >
0.05).
Relationship between the serum HMGB1 and CEA levels 
and GC TNM stage
HMGB1 levels were significantly correlated with depth of
invasion [Spearman correlation coefficients (γs) = 0.273 (p
< 0.05)), and lymph node metastasis [Spearman correla-
tion coefficients (γs) = 0.225 (p < 0.05)) (Table 3), but
CEA levels were not. However, serum HMGB1 levels were
no higher in the M group than in the AGC group without
distant metastasis. There was no significant correlation
between HMGB1 levels and the frequency of lymphovas-
cular or perineural invasion in any of the cancer groups (γs
= 0.067, p > 0.05). The HMGB1 level was significantly cor-
related with stage by UICC-TNM classification except for
stage IV.
Evaluation of the sensitivity and specificity of HMGB1 
compared to CEA for the diagnosis of high-risk lesions and 
EGC
The CEA and HMGB1 cut-off points that gave the best sen-
sitivity and specificity for the diagnosis of high-risk
lesions (IM and adenoma) and cancer (EGC) were evalu-
ated using area under the curve (AUC) analysis (Figure 2,
Table 4 and Table 5). The sensitivity and specificity of
Table 2: Relationship between serum CEA and HMGB1 levels 
and clinical characteristics in all patients
Variables CEA P-value HMGB1 P-value
Age* (γp)0 . 0 7 8 p > 0.05 - 0.044 p > 0.05
Sex† (γs)0 . 0 7 1 p > 0.05 - 0.187 p = 0.005
H. pylori infection† (γs)-  0 . 1 2 1p > 0.05 - 0.046 p > 0.05
CEA*(γp)- - 0 . 0 8 1 p > 0.05
HMGB1*(γp)0 . 0 8 1 p > 0.05 --
* This variable is evaluated by Pearson correlation (for continuous 
variables). γp, Pearson correlation coefficients.
† This variable is evaluated by Spearman correlation (for non-
continuous variables). γs, Spearman correlation coefficients.
Table 3: Relationship between serum CEA or HMGB1 level and pathological characteristics in gastric cancer groups including EGC, 
AGC, and metastatic GC
Variables (γs)C E A P-value¶ HMGB1 P-value¶
Depth of invasion (T stage) 0.118 p > 0.05 0.273 p = 0.011
Lymph node metastases (N stage) 0.131 p > 0.05 0.225 p = 0.039
Pathological differentiation* -0.040 p > 0.05 0.009 p > 0.05
Lymphovascular or perineural invasion 0.105 p > 0.05 0.067, p > 0.05
Tumor location† 0.037 p > 0.05 0.041 p > 0.05
Size of tumor‡ 0.147 p > 0.05 0.457 P = 0.017
Stage§ 0.098 p > 0.05 0.221 p = 0.040
*Gastric cancers are divided into intestinal and diffuse type carcinoma according to Lauren classification of differentiation.
†Gastric cancers are divided into three groups according to tumor location; antrum/body, cardia, diffuse.
‡Gastric cancers are divided into three groups by size; < 3 cm, 3–5 cm and > 5 cm.
§The stage of tumor was defined according to the UICC-TNM classification. Subjects with stage IV were excluded from this analysis.
¶ The relationship between each pathological variable and serum CEA or HMGB1 level in gastric cancer groups including EGC, AGC, and metastatic 
GC was evaluated by Spearman correlation (for non-continuous variables). γs, Spearman correlation coefficients.Journal of Translational Medicine 2009, 7:38 http://www.translational-medicine.com/content/7/1/38
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serum CEA for the diagnosis of cancer (EGC) was 28%
and 79% (cut-off value of 3 ng/ml), and 40% and 66%
(cut-off value of 2.5 ng/ml), respectively. In contrast to
CEA, the sensitivity and specificity of serum HMGB1 lev-
els for the diagnosis of cancer (EGC) was 67% and 71%
(cut-off value of 5.5 ng/ml), and 71% and 67% (cut-off
value of 5 ng/ml). The sensitivity and specificity of serum
CEA levels for the diagnosis of high-risk lesions was 39%
and 76% (cut-off value of 2.5 ng/ml), and 49% and 62%
(cut-off value of 2 ng/ml). In contrast to CEA, the sensitiv-
ity and specificity of serum HMGB1 levels for the diagno-
sis of high-risk lesions was 66% and 72% (cut-off value of
4.5 ng/ml), and 70% and 64% (cut-off value of 4 ng/ml).
There was no difference in sensitivity and specificity of
serum CEA and HMGB1 levels among the cancer groups
with different histologic types (p > 0.05).
Survival analysis GC in relation to serum HMGB1 levels
We evaluated the relationship between the overall survival
and the serum HMGB1 levels in selective metastatic GC
patients (M group). The prognosis of those in the high
HMGB1 level group defined as values above the mean
HMGB1 level (> 14 units) was significantly poorer than
for those in the low level group (values below the mean
(Kaplan Meier method, Log-rank test, n = 42, p = 0.037,
Figure 3).
Discussion
In this study, we evaluated the validity of HMGB1 as a
serological biomarker for GC and demonstrated for the
first time that serum HMGB1 levels are significantly and
sequentially increased in GC according to the progression
of disease based on the theory of gastric carcinogenesis
('gastritis-dysplasia-carcinoma' sequence). Serum
HMGB1 levels were significantly increased in patients
with GC compared to those of patients without cancer.
Although HMGB1 and its receptor, RAGE, are thought to
be elevated in almost all types of cancer [6-13,15-17],
recent studies have revealed that this is not true for all
cases. For example, in lung cancer, the expression of
HMGB1 and RAGE are reduced [24]. Therefore, individual
studies of HMGB1 levels in each type of cancer are needed
to obtain a more accurate understanding of HMGB1-
related mechanisms in cancer development and progres-
sion.
Several studies have reported that HMGB1 was over-
expressed in GC tissue, and the over-expression of
HMGB1 plays an important role in the process of GC tum-
origenesis, expansion, and invasion [15-17]. Quantifica-
tion of HMGB1 expression in tissues could be clinically
useful; however, the utility of the evaluation of HMGB1
over-expression in tissue is somewhat limited because of
the relatively higher-risk, invasiveness and high cost of the
procedures used to obtain the tissue: endoscopic biopsy
or surgical resection.
A recent study found that HMGB1 could be detected in
the serum of cancer patients because it can be passively
released from dying tumor cells, or actively released from
immune cells into the extra-cellular space or serum [1-
5,11]. In the present study, we quantified serum HMGB1
levels in patients who had normal gastric mucosa, IM or
adenoma and carcinoma. The serum levels of HMGB1
were increased sequentially according to GC disease stage
based on the theory of gastric carcinogenesis and HMGB1
levels were significantly different between normal and
high-risk lesions of GC as well as between cancer and non-
cancer. These results are consistent with those of Kuniyasu
et al. in which HMGB1 was measured in GC tissue. We did
not divided the group of patients with high-risk lesions
into an IM and adenoma group because the number of
patients with adenoma was very small (n = 11) and this
number of patients would not have had the statistical
power to detect a difference in mean value between these
two disease groups. However, serum HMGB1 levels
tended to be elevated in patients with adenoma compared
to patients with IM (data was not shown).
We also compared the sensitivity and specificity of serum
HMGB1 with that of CEA, a well-known gastrointestinal
tumor biomarker. Many other studies have shown that
CEA has only 30–40% sensitivity for the detection of EGC
or high-risk lesions and this is very similar to the results of
our study [20,21]. However, the sensitivity and specificity
of serum HMGB1 was about 71% and 67% (cut-off value
of 5 ng/ml) for the detection of cancer (EGC), and 70%
and 64% (cut-off value of 4 ng/ml) for the detection of
Table 4: Comparison of Cut-off Values, Sensitivity, and 
Specificity between serum CEA and HMGB1 levels for the 
screening of high-risk group (IM and adenoma)
CEA (ng/ml) HMGB1 (ng/ml)
Cut-off value (ng/ml) 2.5 2 4.5 4
Sensitivity (%) 39 49 66 70
Specificity (%) 76 62 72 64
Table 5: Comparison of Cut-off Values, Sensitivity, and 
Specificity between serum CEA and HMGB1 levels for the 
screening of EGC group
CEA (ng/ml) HMGB1 (ng/ml)
Cut-off value (ng/ml) 3 2.5 5.5 5
Sensitivity (%) 28 40 67 71
Specificity (%) 79 66 71 67Journal of Translational Medicine 2009, 7:38 http://www.translational-medicine.com/content/7/1/38
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Receiver operator characteristics (ROC) curves generated with serum CEA and HMGB1 levels for the detection of high-risk  lesions (A) including intestinal metaplasia (IM) and adenoma and the detection of EGC (B) Figure 2
Receiver operator characteristics (ROC) curves generated with serum CEA and HMGB1 levels for the detec-
tion of high-risk lesions (A) including intestinal metaplasia (IM) and adenoma and the detection of EGC (B). 
The figures indicate that serum HMGB1 levels demonstrated a higher sensitivity and specificity for the diagnosis of EGC and 
high-risk lesions of GC than CEA. GC, gastric cancer; EGC, early gastric cancer.
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high risk lesions (IM or adenoma). These results are very
dramatic compared with previous studies of other GC
biomarkers [20,21,25,26].
In our study, serum HMGB1 levels did not differ accord-
ing to histologic type (intestinal vs. diffuse) and this is
similar to the results by Kuniyasu et al. [15]. These results
may mean that HMGB1 was not affected by tissue histo-
logic type, and HMGB1 might be better than other
biomarkers such as pepsinogen or gastrin which are
important markers for the intestinal type of GC but not
the diffuse type [25,26].
This study found that serum levels of HMGB1 were asso-
ciated with depth of invasion (T stage), lymph node
metastasis (N stage), tumor size, and poor prognosis.
However, HMGB1 levels were not associated with patient
gender, age, and lymphovascular or and perineural inva-
sion. In addition, HMGB1 levels did not differ between
AGC without distant metastasis and metastatic GC. For
metastasis to occur, tumor cells must pass through a
multi-step process involving a series of sequential and
selective events [27,28]. Therefore, our results might be
caused by the multiple factors in addition to HMGB1 that
contribute to distant metastasis in contrast to tumor
expansion and local invasion. These factors include a vari-
ety of other cytokines or signaling molecules.
In this study, we could not analyze the overall survival of
all cancer patients. Those in the EGC and AGC groups
without distant metastasis were excluded because the
study period was too short to evaluate the survival of
patients with EGC or resectable AGC. For this reason, we
limited the evaluation of the relationship between the
overall survival and the serum HMGB1 levels to patients
in the metastatic GC group. Serum HMGB1 levels were
inversely correlated with the overall survival time of
patients with far-advanced stage of GC (Figure 3). In addi-
Survival analysis of metastatic GC (M) group in relation to serum HMGB1 levels Figure 3
Survival analysis of metastatic GC (M) group in relation to serum HMGB1 levels. The prognosis of subjects in M 
group who had serum HMGB1 levels above the mean (> 14 ng/mL) was significantly poorer than those in M group with levels 
below the mean (Kaplan Meier method, Log-rank test, n = 42, p < 0.05).
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tion, HMGB1 levels were closely related with lymph node
metastasis. In a previous study, lymph node metastasis
was found to be an independent prognostic factor of GC
[29]. Therefore, our data may imply that HMGB1 is asso-
ciated with poor prognosis of GC. However, further stud-
ies to evaluate the exact relationship between HMGB1
levels and prognosis of GC are needed by including all GC
patients and following-up for a long time enough to eval-
uate the overall survival time of all GC patients.
Because HMGB1 is over-expressed in GC, blocking of
HMGB1 production or release, or preventing its interac-
tion with its receptor(s) might provide an important
opportunity for the prevention or treatment of GC as
shown in a colitis-associated cancer model [30]. However,
several studies have demonstrated that HMGB1 mediates
endogenous Toll-like receptor (TLR) activation, and its
increased interaction might enhance the tumor regression
by immunoadjuvant effects after conventional chemo- or
radiotherapy [31,32]. Therefore, further studies are
needed to reach on a deeper understanding of the biology
of HMGB1 in GC and to evaluate its therapeutic useful-
ness.
Conclusion
HMGB1 is a new serologic biomarker for the screening,
diagnosis, and surveillance of GC in high-incidence areas
such as Korea.
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